Tsumura & Co (TSMRF)
28.15
0.00 (0.00%)
USD |
OTCM |
Dec 16, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.138B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 60.13% |
| Valuation | |
| PE Ratio | 13.70 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.028 |
| Price to Book Value | 1.037 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.4534 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2943 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Tsumura & Co is a specialty and generic drug manufacturing company. The company generates most of its revenue through prescription Kampo products, followed by over-the-counter medicines. Tsumura promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company considers strategic collaboration agreements to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. |
| URL | http://www.tsumura.co.jp |
| Investor Relations URL | https://www.tsumura.co.jp/english/ir/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | Mar. 28, 2025 |
| Last Ex-Dividend Date | Sep. 27, 2024 |
Ratings
Profile
| Tsumura & Co is a specialty and generic drug manufacturing company. The company generates most of its revenue through prescription Kampo products, followed by over-the-counter medicines. Tsumura promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company considers strategic collaboration agreements to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. |
| URL | http://www.tsumura.co.jp |
| Investor Relations URL | https://www.tsumura.co.jp/english/ir/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | Mar. 28, 2025 |
| Last Ex-Dividend Date | Sep. 27, 2024 |